MedTrace Logo

Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients

NCT07465458 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2026-03-16

No results posted yet for this study

Summary

This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.

Conditions

  • Renal Carcinoma

Interventions

DEVICE

Radiofrequency Ablation (RFA)

Minimally invasive RFA in T1a renal carcinomas

Sponsors & Collaborators

  • SACMI-Sociedad Aragonesa de Cirugìa Minimamante Invasiva

    collaborator UNKNOWN

  • Humanitas Hospital, Italy

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-03-31
Completion
2028-06-30

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07465458 on ClinicalTrials.gov